Nolibeta (Nebivolol)

Nebivolol, the active ingredient in Nolibeta, is a beta blocker presented as an oral tablet for oral use. It lowers elevated blood pressure and improves cardiac function in patients with heart failure, offering a selective β1‑adrenergic blockade combined with nitric‑oxide‑mediated vasodilation in adult patients.

GNH USA supplies Nolibeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable, bulk shipments to qualified healthcare institutions through a robust quality‑assured supply chain.

Nebivolol is indicated for cardiovascular conditions that involve elevated blood pressure or impaired cardiac output.

Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk in adults. Heart failure (reduced ejection fraction): improves left‑ventricular function and lowers hospitalization rates in patients with chronic heart failure. Elderly patients with hypertension: provides effective blood pressure control with a favorable tolerability profile in older adults.

Nebivolol may be associated with a range of adverse reactions, which are classified by frequency and clinical significance.

Common Side Effects: - Headache - Dizziness - Fatigue - Nasal congestion

Serious or Rare Side Effects: - Severe bradycardia - Heart block - Bronchospasm

When prescribing Nebivolol, clinicians should observe several precautionary measures to ensure patient safety.

Monitor blood pressure: check baseline and periodic readings to assess therapeutic response. Assess heart rate: observe for excessive bradycardia, especially in patients with conduction disorders. Use caution in asthma: β‑blockade may precipitate bronchospasm in susceptible individuals. Review concomitant beta‑blockers: avoid additive effects that could lead to profound hypotension. Adjust in renal impairment: dose may require modification in patients with reduced kidney function. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other beta‑blockers: combined use may cause excessive heart rate reduction and hypotension. - Calcium channel blockers verapamil or diltiazem: can increase plasma levels of nebivolol, raising risk of bradycardia. - Anti‑arrhythmic agents (e.g., amiodarone): may potentiate cardiac conduction slowing.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycemics: nebivolol may mask hypoglycemia symptoms, requiring glucose monitoring. - NSAIDs: may diminish antihypertensive effect, necessitating blood pressure checks.